In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 2, 2017, Pages 444-447

  Ruppen, Corinne ^a   Hemphill, Andrew ^a   Sendi, Parham ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOFILM; BROTH DILUTION; CHEQUERBOARD ASSAY; COLONY FORMING UNIT; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; HUMAN; IN VITRO STUDY; MINIMAL BIOFILM ERADICATION CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SCANNING ELECTRON MICROSCOPY; STREPTOCOCCUS AGALACTIAE; ULTRASOUND; BACTERIAL COUNT; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; OSTEOARTHRITIS; PHYSIOLOGY; PROCEDURES; PROSTHESIS-RELATED INFECTIONS;

ANTI-BACTERIAL AGENTS; BIOFILMS; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, SCANNING; OSTEOARTHRITIS; PENICILLINS; PROSTHESIS-RELATED INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 85014563763     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw447     Document Type: Article

References (15)

1. Sendi P, Christensson B, Uckay I et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. JHosp Infect 2011; 79: 64-9.
2. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
3. Westling K, Aufwerber E, Ekdahl C et al. Swedish guidelines for diagnosis and treatment of infective endocarditis. Scand J Infect Dis 2007; 39: 929-46.
4. Baker CN, Thornsberry C, Facklam RR. Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci. Antimicrob Agents Chemother 1981; 19: 716-25.
5. Glaser P, Rusniok C, Buchrieser C et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol 2002; 45: 1499-513.
6. Holmberg A, Rasmussen M. Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms. Int J Antimicrob Agents 2014; 44: 78-80.
7. Geddes AM, Gould IM. Benzylpenicillin (penicillin G). In: L Grayson, ed. Kucers' The Use of Antibiotics. London: Hodder Arnold, 2010; 5-58.
8. Landersdorfer CB, Bulitta JB, Kinzig M et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48: 89-124.
9. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
10. Olson ME, Ceri H, Morck DW et al. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66: 86-92.
11. Sandoe JAT, Wysome J, West AP et al. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother 2006; 57: 767-70.
12. Sendi P, Furitsch M, Mauerer S et al. Chromosomally and extrachromosomallymediated high-level gentamicin resistance in Streptococcus agalactiae. Antimicrob Agents Chemother 2016; 60: 1702-7.
13. Sendi P, Ericsson M, Olaison L. Infective endocarditis caused by group B Streptococcus: the role of aminoglycoside-combination. J Infect 2012; 64: 127-9.
14. Baudoux P, Bles N, Lemaire S et al. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamicmodels of extracellular and intracellular infections. J Antimicrob Chemother 2007; 59: 246-53.
15. Humphrey JS, Mehta S, Seaber AV et al. Pharmacokinetics of a degradable drug delivery systemin bone. Clin Orthop Relat Res 1998; 218-24.